Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | SRC | P12931 | 2/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4372318 | 0.78 | CYP1A2 (0.42) | HPGDCYP2D6ALDH1A1 | |
| SCHEMBL9007000 | 0.77 | IDO1 (0.38) | CYP2D6ALDH1A1 | |
| SCHEMBL6935686 | 0.76 | TRPA1 (0.45) | TRPA1LMNASRCADRA2AADRA2C | |
| SCHEMBL1305172 | 0.76 | TRPA1 (0.45) | TRPA1LMNASRCADRA2AADRA2C | |
| SCHEMBL4313730 | 0.76 | TRPA1 (0.41) | TRPA1LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL4641824 | 0.74 | TRPA1 (0.44) | TRPA1LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL9222442 | 0.74 | TRPA1 (0.64) | TRPA1LMNAADRA2AADRA2CHIF1A | |
| Hydrochloric Acid SCHEMBL2996840 | 0.74 | L3MBTL1 (0.38) | TRPA1LMNASRCCYP2D6ALDH1A1 | |
| SCHEMBL563813 | 0.73 | LMNA (0.45) | TRPA1LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL12997088 | 0.73 | TRPA1 (0.42) | TRPA1LMNASRCADRA2AADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414143-B2 | Process for the preparation of 4,4-dimethyl-6-ethynylthiochroman | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2008-08-19 | — | — | US | disclosed |
| US-20070238881-A1 | Process for the preparation of tazarotene intermediates and use thereof for the preparation of tazarotene | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2007-10-11 | — | — | US | disclosed |
| US-20060106233-A1 | Process for the preparation of disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2006-05-18 | — | — | US | disclosed |
| WO-2005123713-A1 | PROCESS FOR THE PREPARATION OF DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS | GLENMARK PHARMACEUTICALS LIMITED (US) | 2005-12-29 | — | — | WO | disclosed |
| US-6963002-B2 | Process for the preparation of 4,4-dimethyl-6-ethynylthiochroman | GLENMARK PHARMACEUTICALS LIMITED (US) | 2005-11-08 | — | — | US | disclosed |
| US-20050240029-A1 | Process for the preparation of 4,4-dimethyl-6-ethynylthiochroman | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2005-10-27 | — | — | US | disclosed |
| WO-2005003125-A1 | PROCESS FOR THE PREPARATION OF 4,4-DIMETHYL-6-ETHYNYLTHIOCHROMAN | GLENMARK PHARMACEUTICALS LIMITED (US) | 2005-01-13 | — | — | WO | disclosed |
| US-20050004373-A1 | Process for the preparation of 4,4-dimethyl-6-ethynylthiochroman | GLENMARK GENERICS LTD. (IN) | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238881-A1 | Process for the preparation of tazarotene intermediates and use thereof for the preparation of tazarotene | NAMPT, NAPRT, NNT | TRPA1 3457/4885LMNA 2224/4885SRC 2193/4885 |
| US-20050240029-A1 | Process for the preparation of 4,4-dimethyl-6-ethynylthiochroman | YAP1, SDHA, SDHB | TRPA1 1258/4885LMNA 2438/4885SRC 2903/4885 |
| US-20050004373-A1 | Process for the preparation of 4,4-dimethyl-6-ethynylthiochroman | YAP1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SDHA | TRPA1 1059/4885LMNA 2337/4885SRC 2892/4885 |
| US-20060106233-A1 | Process for the preparation of disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups | CBR3, NR1H2, NR3C2 | TRPA1 2131/4885LMNA 1872/4885SRC 2343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.